TYRA BIOSCIENCES INC (TYRA) Fundamental Analysis & Valuation
NASDAQ:TYRA • US90240B1061
Current stock price
33.785 USD
-1.28 (-3.64%)
At close:
33.785 USD
0 (0%)
After Hours:
This TYRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. TYRA Profitability Analysis
1.1 Basic Checks
- TYRA had negative earnings in the past year.
- TYRA had a negative operating cash flow in the past year.
- TYRA had negative earnings in each of the past 5 years.
- TYRA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -42.44%, TYRA perfoms like the industry average, outperforming 53.01% of the companies in the same industry.
- TYRA's Return On Equity of -46.28% is fine compared to the rest of the industry. TYRA outperforms 63.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.44% | ||
| ROE | -46.28% | ||
| ROIC | N/A |
ROA(3y)-32.28%
ROA(5y)-25.24%
ROE(3y)-35.11%
ROE(5y)-27.1%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- TYRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. TYRA Health Analysis
2.1 Basic Checks
- The number of shares outstanding for TYRA has been increased compared to 1 year ago.
- TYRA has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for TYRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 46.02 indicates that TYRA is not in any danger for bankruptcy at the moment.
- TYRA has a better Altman-Z score (46.02) than 94.95% of its industry peers.
- There is no outstanding debt for TYRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 46.02 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- TYRA has a Current Ratio of 14.67. This indicates that TYRA is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 14.67, TYRA belongs to the top of the industry, outperforming 90.87% of the companies in the same industry.
- A Quick Ratio of 14.67 indicates that TYRA has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 14.67, TYRA belongs to the top of the industry, outperforming 90.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 14.67 | ||
| Quick Ratio | 14.67 |
3. TYRA Growth Analysis
3.1 Past
- TYRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.11%.
EPS 1Y (TTM)-33.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, TYRA will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.73% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-22.8%
EPS Next 2Y-15.55%
EPS Next 3Y-10.67%
EPS Next 5Y11.73%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. TYRA Valuation Analysis
4.1 Price/Earnings Ratio
- TYRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TYRA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as TYRA's earnings are expected to decrease with -10.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.55%
EPS Next 3Y-10.67%
5. TYRA Dividend Analysis
5.1 Amount
- TYRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TYRA Fundamentals: All Metrics, Ratios and Statistics
33.785
-1.28 (-3.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.66
Earnings (Last)03-02 2026-03-02/amc
Earnings (Next)04-30 2026-04-30
Inst Owners108.15%
Inst Owner Change-4.59%
Ins Owners2.93%
Ins Owner Change-3.96%
Market Cap1.82B
Revenue(TTM)N/A
Net Income(TTM)-119.95M
Analysts87.78
Price Target51 (50.95%)
Short Float %14.76%
Short Ratio6.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.17%
Min EPS beat(2)-5.8%
Max EPS beat(2)1.47%
EPS beat(4)3
Avg EPS beat(4)3.6%
Min EPS beat(4)-5.8%
Max EPS beat(4)12.85%
EPS beat(8)6
Avg EPS beat(8)9.2%
EPS beat(12)8
Avg EPS beat(12)5.49%
EPS beat(16)10
Avg EPS beat(16)1.33%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.17%
PT rev (3m)48.94%
EPS NQ rev (1m)0.08%
EPS NQ rev (3m)-3.86%
EPS NY rev (1m)-5.47%
EPS NY rev (3m)-9.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.02 | ||
| P/tB | 7.02 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.01
EYN/A
EPS(NY)-2.47
Fwd EYN/A
FCF(TTM)-1.77
FCFYN/A
OCF(TTM)-1.77
OCFYN/A
SpS0
BVpS4.81
TBVpS4.81
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.44% | ||
| ROE | -46.28% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-32.28%
ROA(5y)-25.24%
ROE(3y)-35.11%
ROE(5y)-27.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 25.82% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 14.67 | ||
| Quick Ratio | 14.67 | ||
| Altman-Z | 46.02 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)123.96%
Cap/Depr(5y)206%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.56%
EPS Next Y-22.8%
EPS Next 2Y-15.55%
EPS Next 3Y-10.67%
EPS Next 5Y11.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.2%
EBIT Next 3Y-13.56%
EBIT Next 5YN/A
FCF growth 1Y-35.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.36%
OCF growth 3YN/A
OCF growth 5YN/A
TYRA BIOSCIENCES INC / TYRA Fundamental Analysis FAQ
What is the fundamental rating for TYRA stock?
ChartMill assigns a fundamental rating of 3 / 10 to TYRA.
Can you provide the valuation status for TYRA BIOSCIENCES INC?
ChartMill assigns a valuation rating of 0 / 10 to TYRA BIOSCIENCES INC (TYRA). This can be considered as Overvalued.
Can you provide the profitability details for TYRA BIOSCIENCES INC?
TYRA BIOSCIENCES INC (TYRA) has a profitability rating of 1 / 10.
What is the earnings growth outlook for TYRA BIOSCIENCES INC?
The Earnings per Share (EPS) of TYRA BIOSCIENCES INC (TYRA) is expected to decline by -22.8% in the next year.